CO5200760A1 - RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8 - Google Patents

RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8

Info

Publication number
CO5200760A1
CO5200760A1 CO00043844A CO00043844A CO5200760A1 CO 5200760 A1 CO5200760 A1 CO 5200760A1 CO 00043844 A CO00043844 A CO 00043844A CO 00043844 A CO00043844 A CO 00043844A CO 5200760 A1 CO5200760 A1 CO 5200760A1
Authority
CO
Colombia
Prior art keywords
alkenyl
alkyl
aryl
heterocyclic
heteroaryl
Prior art date
Application number
CO00043844A
Other languages
Spanish (es)
Inventor
Anthony J Jurewicz
Melvin C Rutledge
Robert P Hertzberg
Gregory M Benson
Simon John Mantell
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5200760A1 publication Critical patent/CO5200760A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Un compuesto de fórmula (I) adecuado para tratar enfermedades mediadas por quimioquinas del grupo seleccionado de malaria, reestenosis, angiogénesis, aterosclerosis, osteoporosis, gingivitis, liberación indeseada de células pluripotenciales, hematopoyéticas y enfermedades de virus respiratorios, herpesvirus y virus de hepatitis que incluyen pero no limitan a la hepatitis B y hepatitis C, en las cuales la quimioquina se une al receptor de IL-8, a o ß en un mamífero.dicho compuesto de fórmula<EMI FILE="00043844_1" ID="1" IMF=JPEG >en la cualX es oxígeno o azufre;R es cualquier resto funcional que tiene un hidrógeno ionizable y un pKa de 10 o menos;R1 se selecciona independientemente entre hidrógeno; halógeno; nitro; ciano; alquilo C1-10 halosustituido; alquilo C1-10; alquenilo C1-10; alcoxi C1-10; alcoxi C1-10 halosustituido;azida; S(O)tR4; hidroxi; hidroxialquilo C1-4; arilo; alquil(C1-4)arilo; ariloxi; alquiloxi(C1-4)arilo; heteroarilo; heteroarilalquilo; alquilo (1-4 heterocíclico, heterocíclico; alquiloxi (C1-4) heteroarilo; alquenil (C2-10) arilo; alquenil (C2-10) heteroarilo; alquenilo C2-10 heterocíclico; NR4R5; alquenilo C2-10-C(O)NR4R5; C(O)NR4R5; C(O)NR4R10; S(O)3H; S(O)3R8; alquilo C1-10-C(O)R11; alquenilo C2-10-C(O)R11; alquenilo C2-10-C(O)OR11; C(O)R11; C(O)OR12, OC(O)R11, NR4C(O)R11; o dos restos R1 juntos pueden formar O-(CH2)SO- o un anillo insaturado de 5 a 6 eslabones;t es 0, o un número entero que tiene un valor de 1 ó 2;s es un número entero que tiene un valor de 1 a 3;R4 y R5 son independientemente hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, alquil(C1-4)arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, alquil(C1-4)heteroarilo opcionalmente sustituido, o alquilo C1-4 heterocíclico, heterocíclico, o R4 y R5 junto con el nitrógeno al que estánunidos forman un anillo de 5 a 7 eslabones que puede comprender opcionalmente otro heteroátomo seleccionado entre O/N/S;Y se selecciona independientemente entre hidrógeno; halógeno; nitro; ciano; alquilo C1-10 halosustituido; alquilo C1-10; alquenilo C2-10; alcoxi C1-10; alcoxi C1-10 halosustituido; azida; S(O)tR4; hidroxi; hidroxialquilo C1-4; arilo; alquil(C1-4)arilo; ariloxi; alquiloxi(C1-4)arilo; heteroarilo; heteroarilalquilo; alquiloxi (C1-4) heteroarilo; alquilo C1-4 heterocíclico, heterocíclico; alquenil(C2-10)arilo; alquenil (C2-10)heteroarilo; alquenilo C2-10 heterocíclico; NR4R5; alquenilo C2-10-C(O)NR4R5; C(O)NR4R5; C(O)NR4R10; S(O)3H; S(O)3R8; alquilo C1-10-C(O)R11; alquenilo C2-10-C(O)R11; alquenilo C2-10-C(O)OR11; C(O)R11; C(O)OR12; OC(O)R11; NR4C(O)R11; o dos restos y juntos pueden formar O-(CH2)sO- o un anillo insaturado de 5 a 6 eslabones;A compound of formula (I) suitable for treating chemokine-mediated diseases of the selected group of malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis, unwanted release of pluripotential cells, hematopoietic and respiratory virus diseases, herpesviruses and hepatitis viruses including but not limited to hepatitis B and hepatitis C, in which chemokine binds to the IL-8 receptor, a or ß in a mammal, said compound of formula <EMI FILE = "00043844_1" ID = "1" MFI = JPEG > in which X is oxygen or sulfur; R is any functional moiety having an ionizable hydrogen and a pKa of 10 or less; R1 is independently selected from hydrogen; halogen; nitro; cyano; C1-10 alkyl halosubstituted; C1-10 alkyl; C1-10 alkenyl; C1-10 alkoxy; halosubstituted C1-10 alkoxy: azide; S (O) tR4; hydroxy; C1-4 hydroxyalkyl; aryl; (C1-4) alkyl aryl; aryloxy; (C1-4) alkyloxy; aryl; heteroaryl; heteroarylalkyl; (1-4 heterocyclic, heterocyclic; alkyloxy (C1-4) heteroaryl; alkenyl (C2-10) aryl; alkenyl (C2-10) heteroaryl; C2-10 alkenyl heterocyclic; NR4R5; C2-10-C alkenyl (O) NR4R5; C (O) NR4R5; C (O) NR4R10; S (O) 3H; S (O) 3R8; C1-10-C (O) R11 alkyl; C2-10-C (O) R11 alkenyl C2 alkenyl -10-C (O) OR11; C (O) R11; C (O) OR12, OC (O) R11, NR4C (O) R11; or two R1 moieties together can form O- (CH2) SO- or a ring unsaturated of 5 to 6 links; t is 0, or an integer that has a value of 1 or 2; s is an integer that has a value of 1 to 3; R4 and R5 are independently hydrogen, C1-4 alkyl optionally substituted, optionally substituted aryl, optionally substituted (C1-4) alkyl, optionally substituted heteroaryl, optionally substituted (C1-4) alkyl, or C1-4 heterocyclic, heterocyclic alkyl, or R4 and R5 together with the nitrogen to which they are attached they form a ring of 5 to 7 links that can optionally comprise another heteroatom selected ent re O / N / S; Y is independently selected from hydrogen; halogen; nitro; cyano; C1-10 alkyl halosubstituted; C1-10 alkyl; C2-10 alkenyl; C1-10 alkoxy; C1-10 alkoxy halosubstituted; azide; S (O) tR4; hydroxy; C1-4 hydroxyalkyl; aryl; (C1-4) alkyl aryl; aryloxy; (C1-4) alkyloxy; aryl; heteroaryl; heteroarylalkyl; (C1-4) alkyloxy heteroaryl; C1-4 alkyl heterocyclic, heterocyclic; (C2-10) alkenyl aryl; (C2-10) alkenyl heteroaryl; C2-10 heterocyclic alkenyl; NR4R5; C2-10-C alkenyl (O) NR4R5; C (O) NR4R5; C (O) NR4R10; S (O) 3H; S (O) 3R8; C1-10-C (O) R11 alkyl; C2-10-C (O) R11 alkenyl; C2-10-C alkenyl (O) OR11; C (O) R11; C (O) OR12; OC (O) R11; NR4C (O) R11; or two moieties and together they can form O- (CH2) sO- or an unsaturated ring of 5 to 6 links;

CO00043844A 1999-06-16 2000-06-13 RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8 CO5200760A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
CO5200760A1 true CO5200760A1 (en) 2002-09-27

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00043844A CO5200760A1 (en) 1999-06-16 2000-06-13 RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8

Country Status (20)

Country Link
EP (1) EP1185261A4 (en)
JP (1) JP2003501459A (en)
KR (1) KR20020010709A (en)
CN (1) CN1355697A (en)
AR (1) AR030391A1 (en)
AU (1) AU766083B2 (en)
BR (1) BR0010802A (en)
CA (1) CA2377341A1 (en)
CO (1) CO5200760A1 (en)
CZ (1) CZ20014471A3 (en)
HK (1) HK1044483A1 (en)
HU (1) HUP0201571A3 (en)
IL (1) IL145761A0 (en)
MX (1) MXPA01013004A (en)
NO (1) NO20016053D0 (en)
NZ (1) NZ514695A (en)
PL (1) PL352232A1 (en)
TR (1) TR200103680T2 (en)
WO (1) WO2000076495A1 (en)
ZA (1) ZA200109479B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
AU2003260280A1 (en) * 2002-08-01 2004-02-23 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1745032B1 (en) * 2004-05-12 2013-07-31 Merck Sharp & Dohme Corp. CXCR1 and CXCR2 chemokine antagonists
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (en) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (en) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (en) * 2007-01-29 2008-08-14 Japan Health Science Foundation New hepatitis c virus inhibitor
KR100982661B1 (en) * 2008-04-22 2010-09-17 전남대학교산학협력단 Pharmaceutical composition for the prevention and treatment of malaria containing a compound that inhibits plasmincin II activity as an active ingredient and a method for treating malaria using the same
KR100970940B1 (en) * 2010-05-03 2010-07-20 전남대학교산학협력단 Pharmaceutical composition for preventing and treating malaria comprising compounds that inhibit Plasmepsin II activity and the method of treating malaria using thereof
US10093617B1 (en) * 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 receptor antagonists
WO2000016768A1 (en) * 1998-09-18 2000-03-30 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
ZA200109479B (en) 2002-11-18
PL352232A1 (en) 2003-08-11
TR200103680T2 (en) 2002-07-22
BR0010802A (en) 2002-02-19
EP1185261A4 (en) 2004-02-25
CA2377341A1 (en) 2000-12-21
EP1185261A1 (en) 2002-03-13
MXPA01013004A (en) 2002-07-30
CZ20014471A3 (en) 2002-08-14
NO20016053L (en) 2001-12-11
HUP0201571A3 (en) 2002-11-28
AR030391A1 (en) 2003-08-20
IL145761A0 (en) 2002-07-25
NZ514695A (en) 2004-05-28
NO20016053D0 (en) 2001-12-11
HK1044483A1 (en) 2002-10-25
JP2003501459A (en) 2003-01-14
WO2000076495A1 (en) 2000-12-21
AU5741300A (en) 2001-01-02
AU766083B2 (en) 2003-10-09
CN1355697A (en) 2002-06-26
HUP0201571A2 (en) 2002-08-28
KR20020010709A (en) 2002-02-04

Similar Documents

Publication Publication Date Title
CO5200760A1 (en) RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8
CO5280059A1 (en) DERIVATIVES OF 2-OX-1-PIRROLIDINA, PROCEWO TO PREPARE THEM AND ITS APPLICATIONS
CO5031286A1 (en) CIANO GUANADINA COMPOUNDS AS ANTAGONISTS OF IL-8 RECEPTORS AND PREPARATION METHOD
CO4890843A1 (en) IL-8 RECEPTORS ANTAGONISTS OF IL-8
CO5160294A1 (en) PHARMACEUTICAL COMPOSITION THAT INHIBITES OR STOPS THE GROWTH OF VIRUSES IN PARTICULARLY ANIMALS MAMMALS VIRUSS IN ANIMALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR005706A1 (en) EGFR INHIBITORS OF 4-AMINOQUINZOLINE, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, USE OF THE SAME FOR THE PREPARATION OF A MEDICINE USEFUL AS AN ANTINEOPLASTIC AGENT
PE84099A1 (en) BENCIMIDAZOLE DERIVATIVES
PE20020206A1 (en) METHODS AND COMPOSITIONS INCLUDING NUCLEOSIDES TO TREAT THE HEPATITIS C VIRUS
PE20020254A1 (en) PYRIDINE DERIVATIVES
CO4990929A1 (en) DIFENILUREA COMPOUNDS SUBSTITUTED WITH SULFONAMIDES AS ANTAGONISTS OF IL-8 RECEPTORS
AR015425A1 (en) BENZOTIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION
UY26093A1 (en) AP2 INHIBITORS OF BIPHENYLS CONTAINING HETERO-CYCLE COMPOUNDS AND METHOD
AR032398A1 (en) SULFONAMIDE ESCUARAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND TO PREPARE SUCH COMPOSITION
CO5140093A1 (en) MODIFIED EPOTILONES C 21
DK1485359T3 (en) sodium
AR033803A1 (en) DIANILINO ESCUARANO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, AND THE USE OF THE SAME IN THE MANUFACTURE OF MEDICINES TO TREAT CHEMIOQUINE MEDIUM-RELATED DISEASES
BR0014199A (en) Biphenyl derivatives as nhe-3 inhibitors
BG102214A (en) Derivatives of azetidinons for the treatment of atherosclerosis
CO5190696A1 (en) ANTAGONISTS OF IL-8 RECEIVERS
AR037940A1 (en) PIRIDOQUINOXALINA ANTIVIRAL COMPOUNDS
AR008331A1 (en) ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CO5190710A1 (en) ANTAGONISTS OF AN IL-8 RECEIVER AN IL-8 RECEIVER
DE69930357D1 (en) From the sea bass Epinephelus coioides derived immortal cell line and its uses
CO5190712A1 (en) ANTAGONISTS OF IL-8 RECEIVERS OF IL-8 RECEIVERS
CO5170528A1 (en) ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8

Legal Events

Date Code Title Description
FC Application refused